GAA loading, cardiometabolic risk and inflammation
- Post by: Admin
- January 1, 2018
- No Comment
In this open-label trial, we examined the effects of the 10-week supplementation with 3 grams per day of GAA on biomarkers of cardiometabolic risk and inflammation in 20 apparently healthy volunteers (10 men and 10 women; age 22.0 ± 2.3 years). GAA had no significant effects on serum hsCRP, HDL cholesterol, insulin, and triglycerides. Clinical enzymes were mainly unaffected by GAA supplementation. Alkaline phosphatase levels increased after GAA intervention (13.6% corresponding to 9.5 IU/L; p = 0.01), but mean values remained within normal ranges (44–147 IU/L). Supplementation with GAA yielded a statistically significant increase of the mean serum ferritin levels at post-administration (7.5% corresponding to 4.1 µg/L; p = 0.012). We found that supplemental GAA has no significant effects on traditional biomarkers of cardiometabolic risk and inflammation in healthy volunteers. Neither serum hsCRP nor insulin was affected by 10-week GAA administration, with a ratio of triglycerides to HDL cholesterol (an indicator of atherogenic profile) remaining essentially unaffected by the intervention. This implies that there is no major cardiometabolic burden of medium-term GAA intervention in healthy humans.